Revenue growth has contracted significantly, with the company reporting a 25.96% year-over-year decline and a 2026Q1 gross margin of only 42.7%.
| Sales/Revenue | 414.58K | 456.02K | 615.87K | 731.49K | 8.94K | 0 |
| Revenue Growth % | -18.88% | -25.96% | -15.81% | 8083.16% | - | - |
| Cost of Goods Sold | 197.26K | 205.63K | 235.91K | 299.99K | 4.09K | 0 |
| COGS % of Revenue | - | 45.09% | 38.3% | 41.01% | 45.74% | - |
| Gross Profit | 217.32K | 250.39K | 379.96K | 431.5K | 4.85K | 0 |
| Gross Margin % | 52.42% | 54.91% | 61.7% | 58.99% | 54.26% | - |
| Gross Profit Growth % | - | -34.1% | -11.94% | 8796.93% | - | - |
| Operating Expenses | 17.65M | 19.41M | 8.35M | 9.65M | 2M | 17.52K |
| OpEx % of Revenue | - | 4255.37% | 1356.12% | 1319.27% | 22333.95% | - |
| Selling, General & Admin | 2.23M | 16.72M | 7.9M | 5.42M | 2M | 17.52K |
| SG&A % of Revenue | - | 3666.83% | 1282.44% | 740.53% | 22333.95% | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 3.11M | 2.68M | 453.79K | 4.23M | 0 | 0 |
| Operating Income | -17.43M | -19.15M | -7.97M | -9.22M | -1.99M | -17.52K |
| Operating Margin % | -4203.81% | -4200.46% | -1294.42% | -1260.28% | -22279.7% | - |
| Operating Income Growth % | - | -140.28% | 13.53% | -362.89% | -11267.48% | - |
| EBITDA | -15.84M | -17.43M | -7.25M | -9.19M | -1.99M | -17.52K |
| EBITDA Margin % | -3821.25% | -3822.36% | -1177.27% | -1256.88% | -22236.48% | - |
| EBITDA Growth % | -70.56% | -140.41% | 21.14% | -362.54% | -11245.43% | - |
| D&A (Non-Cash Add-back) | 1.59M | 1.72M | 721.53K | 24.89K | 3.86K | 0 |
| EBIT | -19.09M | -20.54M | -8.69M | -8.12M | -1.99M | -17.52K |
| Net Interest Income | -394.03K | -103.51K | -13.7K | 0 | -6.47K | -181 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 394.03K | 103.51K | 13.7K | 0 | 6.47K | 181 |
| Other Income/Expense | -1.78M | -1.49M | -735K | 6.47K | -6.47K | -181 |
| Pretax Income | -19.21M | -20.64M | -8.71M | -9.21M | -2M | -17.7K |
| Pretax Margin % | -4632.92% | -4526.86% | -1413.77% | -1259.4% | -22352.11% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -19.21M | -20.64M | -8.71M | -9.21M | -2M | -17.7K |
| Net Margin % | -4632.94% | -4526.86% | -1413.6% | -1259.4% | -22352.11% | - |
| Net Income Growth % | -71.84% | -137.12% | 5.5% | -361.07% | -11187.81% | - |
| Net Income (Continuing) | -19.21M | -20.64M | -8.71M | -9.21M | -2M | -17.7K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.53K | -1.54K | -1.08K | 0 | 0 | 0 |
| EPS (Diluted) | -1.91 | -2.05 | -4.40 | -8.58 | -1.73 | -0.02 |
| EPS Growth % | 56.23% | 53.4% | 48.73% | -395.7% | -9679.1% | - |
| EPS (Basic) | - | -2.05 | -4.40 | -8.58 | -1.73 | -0.02 |
| Diluted Shares Outstanding | 10.07M | 10.07M | 1.98M | 1.07M | 1.15M | 997.67K |
| Basic Shares Outstanding | 10.07M | 10.07M | 1.98M | 1.07M | 1.15M | 997.67K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Unsustainable customer acquisition costs
As evidenced by the most recent quarterly filings, MGRX has experienced a significant 25.96% year-over-year revenue decline, signaling that the company's direct-to-consumer telemedicine model is struggling to maintain a stable subscriber base or effectively convert new traffic into recurring, long-term revenue streams.
The consistent downward trend in top-line performance suggests that the company's niche focus on flavored sublingual medications has failed to gain sufficient market traction. Investors should monitor whether this contraction reflects a fundamental lack of product-market fit or an inability to compete with larger, better-capitalized telehealth platforms.
Based on reported financial statements, MGRX's gross margins have fluctuated significantly, reaching a low of 42.7% in 2026Q1, which highlights the inherent instability in managing third-party compounding pharmacy costs and variable ingredient procurement within a low-volume, high-churn business environment.
The inability to maintain consistent gross margins suggests a lack of pricing power and vulnerability to fluctuations in pharmacy service costs. This margin volatility complicates the path to profitability, as the company lacks the scale necessary to absorb these variable cost pressures effectively.
According to historical income statement data, MGRX's operating margins have remained deeply negative, with a staggering -4200.46% margin in recent periods, indicating that the company's fixed operating expenses and marketing outlays are vastly disproportionate to the current level of revenue generation.
The extreme disparity between gross profit and operating expenses suggests that the company is currently unable to achieve the operating leverage required for a sustainable business model. The current cost structure appears to be fundamentally misaligned with the company's ability to generate meaningful top-line growth.
As reported in recent SEC filings, the quality of MGRX's earnings is severely compromised by persistent net losses and significant stock-based compensation, which, when combined with a cash balance of only $1.48M, raises substantial concerns regarding the company's long-term financial viability.
The reliance on equity-based compensation during periods of extreme net losses suggests a misalignment between management incentives and shareholder value creation. Investors should be wary of the potential for further dilutive capital raises, as the current burn rate appears to be rapidly depleting the company's limited cash reserves.
Based on the provided financial data, the most significant challenge to the MGRX narrative is the unsustainable burn-to-revenue ratio, which suggests that the company may be facing an existential liquidity crisis rather than a temporary period of growth-related investment.
Short-sellers would likely focus on the company's inability to scale revenue while simultaneously depleting cash, which may indicate that the current business model is fundamentally flawed. The lack of a clear path to positive cash flow warrants extreme caution regarding the company's ability to survive without significant external intervention.
Quick answers to the most common questions about buying MGRX stock.
For fiscal year 2025, Mangoceuticals, Inc. (MGRX) reported total revenue of $0.5M.
Mangoceuticals, Inc. (MGRX) reported a net loss of $20.6M for the fiscal year ending 2025.
Mangoceuticals, Inc. (MGRX) reported an operating income of $-19.2M, resulting in an operating profit margin of -4200.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Mangoceuticals, Inc. (MGRX) generated $0.3M in gross profit for the year, representing a gross profit margin of 54.9%. This demonstrates the company's core pricing power and production efficiency.